See more : archTIS Limited (AR9.AX) Income Statement Analysis – Financial Results
Complete financial analysis of MERCK Kommanditgesellschaft auf Aktien (MKGAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MERCK Kommanditgesellschaft auf Aktien, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Unipar Carbocloro S.A. (UNIP3.SA) Income Statement Analysis – Financial Results
- HK inno.N Corporation (195940.KQ) Income Statement Analysis – Financial Results
- AmRest Holdings SE (ARHOF) Income Statement Analysis – Financial Results
- Silver Grail Resources Ltd. (SVGAF) Income Statement Analysis – Financial Results
- Merchants & Marine Bancorp, Inc. (MNMB) Income Statement Analysis – Financial Results
MERCK Kommanditgesellschaft auf Aktien (MKGAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.merckgroup.com
About MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.99B | 22.23B | 19.69B | 17.53B | 16.15B | 14.84B | 15.33B | 15.02B | 12.84B | 11.50B | 11.10B | 11.17B | 10.28B | 9.29B | 7.75B | 7.56B | 7.06B | 6.26B | 5.87B | 5.34B | 7.20B | 7.40B |
| Cost of Revenue | 8.56B | 8.53B | 7.35B | 6.84B | 6.01B | 5.38B | 5.32B | 5.20B | 4.08B | 4.06B | 3.56B | 3.74B | 2.79B | 2.39B | 2.03B | 1.91B | 1.78B | 2.41B | 2.37B | 2.25B | 3.57B | 3.79B |
| Gross Profit | 12.44B | 13.71B | 12.34B | 10.70B | 10.15B | 9.45B | 10.01B | 9.82B | 8.77B | 7.44B | 7.54B | 7.44B | 7.49B | 6.91B | 5.72B | 5.65B | 5.28B | 3.84B | 3.50B | 3.09B | 3.63B | 3.61B |
| Gross Profit Ratio | 59.23% | 61.65% | 62.66% | 61.02% | 62.82% | 63.72% | 65.29% | 65.38% | 68.26% | 64.66% | 67.92% | 66.55% | 72.87% | 74.32% | 73.81% | 74.78% | 74.78% | 61.43% | 59.64% | 57.87% | 50.40% | 48.72% |
| Research & Development | 2.45B | 2.52B | 2.41B | 2.29B | 2.27B | 2.23B | 2.14B | 1.98B | 1.71B | 1.70B | 1.50B | 1.51B | 1.52B | 1.40B | 1.34B | 1.23B | 1.03B | 751.60M | 713.00M | 599.00M | 604.60M | 608.20M |
| General & Administrative | 1.39B | 1.31B | 1.24B | 1.19B | 1.15B | 993.00M | 930.00M | 854.00M | 719.90M | 608.60M | 562.40M | 552.20M | 1.01B | 478.20M | 424.90M | 446.20M | 444.70M | 386.70M | 354.70M | 329.20M | 412.40M | 468.00M |
| Selling & Marketing | 3.91B | 4.10B | 3.71B | 3.57B | 3.65B | 3.41B | 3.69B | 3.50B | 3.27B | 2.39B | 2.33B | 2.41B | 2.39B | 2.23B | 2.27B | 2.10B | 1.93B | 1.48B | 1.47B | 1.34B | 1.72B | 1.77B |
| SG&A | 5.31B | 5.40B | 4.96B | 4.76B | 4.81B | 4.40B | 4.62B | 4.35B | 3.99B | 2.99B | 2.89B | 2.96B | 3.40B | 2.71B | 2.70B | 2.54B | 2.38B | 1.86B | 1.82B | 1.67B | 2.13B | 2.24B |
| Other Expenses | 1.08B | 1.03B | 777.00M | 841.00M | 767.00M | 521.00M | 681.00M | 431.00M | 342.80M | 65.80M | 62.70M | 70.80M | 68.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.83B | 8.95B | 8.14B | 7.89B | 7.84B | 7.58B | 7.63B | 7.53B | 6.60B | 5.68B | 5.38B | 5.55B | 6.50B | 5.80B | 5.07B | 4.52B | 4.30B | 2.74B | 2.62B | 2.05B | 3.05B | 3.11B |
| Cost & Expenses | 17.38B | 17.48B | 15.49B | 14.72B | 13.85B | 12.97B | 12.95B | 12.73B | 10.68B | 9.74B | 8.94B | 9.28B | 9.29B | 8.19B | 7.10B | 6.43B | 6.08B | 5.15B | 4.99B | 4.30B | 6.62B | 6.90B |
| Interest Income | 121.00M | 71.00M | 46.00M | 39.00M | 66.00M | 55.00M | 26.00M | 20.00M | 32.00M | 30.60M | 30.10M | 35.60M | 57.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 272.00M | 235.00M | 272.00M | 387.00M | 476.00M | 339.00M | 348.00M | 342.00M | 348.80M | 222.70M | 248.00M | 301.20M | 319.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88B | 1.80B | 1.71B | 1.76B | 1.91B | 1.75B | 1.76B | 1.81B | 1.51B | 1.36B | 1.46B | 1.40B | 1.60B | 1.26B | 1.00B | 1.22B | 923.60M | 303.00M | 289.50M | 375.00M | 470.50M | 425.20M |
| EBITDA | 5.69B | 6.55B | 5.96B | 4.73B | 4.16B | 3.60B | 4.25B | 4.43B | 3.35B | 3.14B | 3.10B | 2.41B | 2.76B | 2.36B | 1.65B | 2.35B | 1.90B | 1.10B | 1.17B | 1.42B | 1.01B | 920.00M |
| EBITDA Ratio | 27.08% | 30.33% | 30.28% | 26.97% | 26.18% | 25.00% | 27.29% | 27.90% | 28.19% | 27.73% | 33.03% | 29.29% | 23.65% | 25.45% | 21.65% | 36.34% | 37.90% | 19.00% | 18.72% | 26.57% | 17.32% | 13.20% |
| Operating Income | 3.61B | 4.47B | 4.18B | 2.99B | 2.12B | 1.73B | 2.53B | 2.48B | 1.84B | 1.76B | 1.61B | 963.60M | 985.10M | 1.11B | 620.90M | 731.40M | 975.70M | 1.11B | 955.60M | 1.04B | 579.30M | 494.80M |
| Operating Income Ratio | 17.19% | 20.12% | 21.23% | 17.02% | 13.13% | 11.64% | 16.47% | 16.51% | 14.35% | 15.32% | 14.52% | 8.62% | 9.59% | 11.94% | 8.01% | 9.68% | 13.83% | 17.67% | 16.28% | 19.54% | 8.04% | 6.69% |
| Total Other Income/Expenses | -125.00M | -187.00M | -255.00M | -355.00M | -385.00M | -266.00M | -294.00M | -327.00M | -356.00M | -205.00M | -222.20M | -1.13B | -293.30M | -248.30M | -159.00M | -156.50M | -1.09B | 167.90M | 11.90M | -82.70M | -156.70M | -83.20M |
| Income Before Tax | 3.48B | 4.29B | 3.92B | 2.63B | 1.74B | 1.46B | 2.22B | 2.15B | 1.49B | 1.56B | 1.39B | 709.00M | 851.10M | 861.10M | 486.40M | 574.90M | -110.90M | 1.27B | 893.40M | 960.80M | 422.60M | 411.60M |
| Income Before Tax Ratio | 16.60% | 19.28% | 19.93% | 15.00% | 10.74% | 9.85% | 14.51% | 14.34% | 11.57% | 13.54% | 12.52% | 6.35% | 8.28% | 9.27% | 6.28% | 7.61% | -1.57% | 20.35% | 15.22% | 17.99% | 5.87% | 5.56% |
| Income Tax Expense | 650.00M | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M | -386.00M | 521.00M | 368.00M | 392.20M | 179.50M | 130.00M | 222.10M | 219.60M | 109.70M | 195.80M | -23.10M | 272.20M | 220.70M | 288.90M | 204.90M | 196.40M |
| Net Income | 2.82B | 3.33B | 3.06B | 1.99B | 1.32B | 3.37B | 2.61B | 1.63B | 1.12B | 1.16B | 1.20B | 566.70M | 606.50M | 641.50M | 376.70M | 379.10M | 3.52B | 1.00B | 672.70M | 671.90M | 217.70M | 215.20M |
| Net Income Ratio | 13.45% | 14.96% | 15.52% | 11.33% | 8.17% | 22.74% | 17.00% | 10.84% | 8.68% | 10.06% | 10.84% | 5.07% | 5.90% | 6.90% | 4.86% | 5.02% | 49.88% | 16.00% | 11.46% | 12.58% | 3.02% | 2.91% |
| EPS | 6.49 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| EPS Diluted | 6.50 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| Weighted Avg Shares Out | 435.13M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.40M | 434.78M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
| Weighted Avg Shares Out (Dil) | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.89M | 434.40M | 435.55M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
Merck KGaA: Company With A Potential Upside
Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and electronics. Despite a conservative dividend yield, Merck KGaA has potential for...
Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs.
Merck KGaA says MS drug has blockbuster potential; key data expected in December
The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged that it may cause liver damage.
Merck KGaA raises prospect of return to sales growth next year
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.
Exscientia stock surges on Merck KGaA partnership
Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year collaboration with German science and technology company Merck KGaA, which could be worth hundreds of millions of dollars. The collaboration...
Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025
Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in its 2025 targets despite reducing its full-year guidance for 2023. Anticipated double-digit revenue growth in 2024...
Merck KGaA (MKGAF) Q2 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chief Executive Officer Helene von Roeder - Chief Financial Officer Matthias Heinzel - Chief...
Ranking The Diversified Healthcare Giants
The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.
Trim Big Pharma For Merck KgaA
Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investment.
MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q3 2022 Results - Earnings Call Transcript
MERCK Kommanditgesellschaft auf Aktien (OTCPK:MKGAF) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhnert - Group CFO Matthias Heinzel - CEO, Life Science Kai...
Source: https://incomestatements.info
Category: Stock Reports